

Javed Butler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1284958/publications.pdf>

Version: 2024-02-01

590
papers

55,875
citations

4942

84
h-index

1561

217
g-index

591
all docs

591
docs citations

591
times ranked

33883
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2013, 62, e147-e239. | 1.2 | 7,017 |
| 2 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726. | 1.0 | 5,558 |
| 3 | Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424. | 13.9 | 2,821 |
| 4 | 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327. | 1.6 | 2,335 |
| 5 | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803. | 1.2 | 2,256 |
| 6 | Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619. | 1.6 | 2,206 |
| 7 | Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461. | 13.9 | 2,143 |
| 8 | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017, 136, e137-e161. | 1.6 | 2,130 |
| 9 | The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133. | 1.2 | 1,640 |
| 10 | SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829. | 6.3 | 816 |
| 11 | Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 351-366. | 1.2 | 775 |
| 12 | Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2020, 382, 1883-1893. | 13.9 | 753 |
| 13 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, 2021, 23, 352-380. | 2.9 | 630 |
| 14 | 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488. | 1.2 | 549 |
| 15 | Mitochondrial function as a therapeutic target in heart failure. Nature Reviews Cardiology, 2017, 14, 238-250. | 6.1 | 525 |
| 16 | Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904. | 6.3 | 425 |
| 17 | Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293. | 1.2 | 424 |
| 18 | Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533. | 3.8 | 410 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Myocardial Interstitial Fibrosis in Heart Failure. Journal of the American College of Cardiology, 2018, 71, 1696-1706. | 1.2 | 406 |
| 20 | Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085. | 3.8 | 403 |
| 21 | Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413. | 0.7 | 362 |
| 22 | Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 73, 2365-2383. | 1.2 | 327 |
| 23 | Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251. | 3.8 | 288 |
| 24 | Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. European Heart Journal, 2017, 38, 1119-1127. | 1.0 | 285 |
| 25 | Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534. | 0.7 | 283 |
| 26 | Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025. | 3.0 | 280 |
| 27 | Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. JACC: Heart Failure, 2015, 3, 136-145. | 1.9 | 265 |
| 28 | Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 280-288. | 1.2 | 259 |
| 29 | Empagliflozin in Heart Failure. Circulation, 2020, 142, 1028-1039. | 1.6 | 252 |
| 30 | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Failure, 2016, 9, e002661. | 1.6 | 241 |
| 31 | The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229. | 6.1 | 238 |
| 32 | Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336. | 1.6 | 222 |
| 33 | Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349. | 1.6 | 217 |
| 34 | Incident Heart Failure Prediction in the Elderly. Circulation: Heart Failure, 2008, 1, 125-133. | 1.6 | 216 |
| 35 | Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287. | 2.9 | 205 |
| 36 | Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950. | 3.0 | 199 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370. | 1.0 | 199 |
| 38 | The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163. | 1.0 | 195 |
| 39 | Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294. | 1.6 | 195 |
| 40 | Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569. | 1.2 | 193 |
| 41 | Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 464-472. | 1.9 | 179 |
| 42 | Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , 2015, 4, . | 1.6 | 174 |
| 43 | Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512. | 3.8 | 170 |
| 44 | Reframing the association and significance of comorbidities in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 744-758. | 2.9 | 169 |
| 45 | Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321. | 1.6 | 168 |
| 46 | Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 995. | 3.0 | 164 |
| 47 | Epidemiology of Incident Heart Failure in a Contemporary Elderly Cohort. <i>Archives of Internal Medicine</i> , 2009, 169, 708. | 4.3 | 161 |
| 48 | Cardiovascular Aging and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 804-813. | 1.2 | 160 |
| 49 | Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 935-944. | 1.2 | 160 |
| 50 | Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, 868-875. | 0.7 | 159 |
| 51 | Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306. | 4.3 | 157 |
| 52 | Evaluation of the effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278. | 2.9 | 155 |
| 53 | Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. <i>JAMA Cardiology</i> , 2018, 3, 1011. | 3.0 | 146 |
| 54 | Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy. <i>Circulation Research</i> , 2017, 120, 332-340. | 2.0 | 144 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , 2019, 21, 163-171. | 2.9 | 144 |
| 56 | Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424. | 1.0 | 144 |
| 57 | Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 704-712. | 1.2 | 142 |
| 58 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104. | 1.9 | 141 |
| 59 | The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400. | 2.9 | 139 |
| 60 | Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , 2021, 6, 743. | 3.0 | 125 |
| 61 | Therapeutic Targets in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2188-2198. | 1.2 | 124 |
| 62 | Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 798-809. | 2.2 | 124 |
| 63 | Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175. | 1.9 | 120 |
| 64 | Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710. | 1.0 | 117 |
| 65 | Patient Selection in Heart Failure With Preserved Ejection Fraction Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1668-1682. | 1.2 | 116 |
| 66 | Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines—Heart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20. | 1.2 | 115 |
| 67 | Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212. | 1.0 | 114 |
| 68 | Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008335. | 1.6 | 113 |
| 69 | Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002843. | 1.6 | 109 |
| 70 | Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019, 7, 1-12. | 1.9 | 109 |
| 71 | Coenzyme Q10 and Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002639. | 1.6 | 108 |
| 72 | The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. <i>Nature Medicine</i> , 2022, 28, 809-813. | 15.2 | 107 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1595-1603. | 0.3 | 106 |
| 74 | Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193. | 1.6 | 106 |
| 75 | Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407. | 1.2 | 105 |
| 76 | Global left atrial failure in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1307-1320. | 2.9 | 104 |
| 77 | Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3370-3372. | 1.2 | 102 |
| 78 | Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1033-H1042. | 1.5 | 101 |
| 79 | The Importance of NLRP3 Inflammasome in Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 586-593. | 0.7 | 97 |
| 80 | Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. <i>International Journal of Cardiology</i> , 2014, 172, 115-121. | 0.8 | 96 |
| 81 | Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680. | 1.0 | 96 |
| 82 | Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956. | 2.9 | 95 |
| 83 | Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 237-248. | 1.9 | 94 |
| 84 | Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850. | 1.2 | 94 |
| 85 | Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392. | 1.2 | 94 |
| 86 | Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392. | 2.9 | 93 |
| 87 | Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343. | 1.2 | 90 |
| 88 | Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 9-13. | 2.9 | 90 |
| 89 | N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939. | 1.9 | 88 |
| 90 | Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. <i>Journal of Cardiac Failure</i> , 2020, 26, 462-463. | 0.7 | 87 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1166-1187. | 1.2 | 87 |
| 92 | Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1575-1589. | 1.2 | 86 |
| 93 | Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. <i>European Journal of Heart Failure</i> , 2015, 17, 1231-1239. | 2.9 | 85 |
| 94 | Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791. | 2.9 | 84 |
| 95 | Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13. | 1.9 | 84 |
| 96 | Advance Directives Among Hospitalized Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 112-121. | 1.9 | 78 |
| 97 | Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 1531-1533. | 13.9 | 78 |
| 98 | Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. <i>JAMA Cardiology</i> , 2020, 5, 714. | 3.0 | 76 |
| 99 | Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3298-3309. | 1.4 | 76 |
| 100 | Concomitant Diabetes Mellitus and Heart Failure. <i>Current Problems in Cardiology</i> , 2015, 40, 7-43. | 1.1 | 75 |
| 101 | Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. <i>JACC: CardioOncology</i> , 2019, 1, 54-65. | 1.7 | 74 |
| 102 | Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152. | 1.2 | 74 |
| 103 | Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65. | 2.9 | 73 |
| 104 | Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 472-485. | 2.9 | 71 |
| 105 | Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005. | 2.9 | 71 |
| 106 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020. | 1.0 | 71 |
| 107 | Population Risk Prediction Models for Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 438-447. | 1.6 | 69 |
| 108 | Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039. | 1.2 | 69 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. <i>JACC: Heart Failure</i> , 2015, 3, 193-201. | 1.9 | 68 |
| 110 | Trends in prevalence of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 1032-1042. | 2.9 | 68 |
| 111 | Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 314. | 3.8 | 68 |
| 112 | Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441. | 2.9 | 67 |
| 113 | Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840. | 1.9 | 65 |
| 114 | Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 | 2.9 | 65 |
| 115 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117. | 1.0 | 65 |
| 116 | Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218. | 1.6 | 63 |
| 117 | Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522. | 3.0 | 62 |
| 118 | Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 | 0.7 | 61 |
| 119 | Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 789. | 3.8 | 58 |
| 120 | Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 | 1.9 | 58 |
| 121 | High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326. | 0.7 | 57 |
| 122 | Medication dosing for heart failure with reduced ejection fraction – opportunities and challenges. <i>European Journal of Heart Failure</i> , 2019, 21, 286-296. | 2.9 | 57 |
| 123 | Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598. | 1.2 | 56 |
| 124 | Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 727-732. | 1.2 | 56 |
| 125 | Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , 2021, 143, 2370-2383. | 1.6 | 56 |
| 126 | Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 95-102. | 1.7 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , 2020, 13, e006605. | 1.6 | 55 |
| 128 | Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332. | 1.2 | 55 |
| 129 | Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. , 2017, 176, 32-39. | | 54 |
| 130 | Comparison of Multidetector Computed Tomography and Two-Dimensional Transthoracic Echocardiography for Left Ventricular Assessment in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2007, 99, 247-249. | 0.7 | 53 |
| 131 | Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031. | 2.9 | 52 |
| 132 | Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 528-537. | 1.9 | 52 |
| 133 | Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, . | 1.3 | 52 |
| 134 | Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348. | 1.2 | 52 |
| 135 | Association of Physical Activity or Fitness With Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 853-861. | 1.6 | 51 |
| 136 | Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta-Analysis. <i>Journal of the American Heart Association</i> , 2015, 4, e001364. | 1.6 | 51 |
| 137 | Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281. | 0.7 | 50 |
| 138 | Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390. | 1.2 | 50 |
| 139 | Impact of Autonomic Regulation Therapy in Patients with Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005879. | 1.6 | 50 |
| 140 | Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. <i>JAMA Network Open</i> , 2020, 3, e2012469. | 2.8 | 50 |
| 141 | Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2076-2085. | 1.2 | 50 |
| 142 | Device Therapy in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 931-956. | 1.2 | 50 |
| 143 | Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. <i>Atherosclerosis</i> , 2016, 245, 181-186. | 0.4 | 49 |
| 144 | Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088. | 1.6 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460. | 1.6 | 49 |
| 146 | Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€“OMicsâ€™™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181. | 2.3 | 48 |
| 147 | Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32. | 0.7 | 48 |
| 148 | Redefining Heart Failure With a Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1761. | 3.8 | 48 |
| 149 | In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012. | 1.2 | 48 |
| 150 | Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. <i>American Heart Journal</i> , 2022, 253, 86-98. | 1.2 | 48 |
| 151 | Management of Comorbid Diabetes Mellitus and Worsening Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2379. | 3.8 | 47 |
| 152 | Randomized Clinical Trial of an Integrated Self-Care Intervention for Persons With Heart Failure and Diabetes: Quality of Life and Physical Functioning Outcomes. <i>Journal of Cardiac Failure</i> , 2015, 21, 719-729. | 0.7 | 47 |
| 153 | Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 47 |
| 154 | Cardiovascular implications of COVID-19 versus influenza infection: a review. <i>BMC Medicine</i> , 2020, 18, 403. | 2.3 | 47 |
| 155 | Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136. | 1.9 | 47 |
| 156 | Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HF rEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480. | 1.9 | 47 |
| 157 | Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, . | 1.6 | 46 |
| 158 | Postmarketing Adverse Events Related to the CardioMEMS HF System. <i>JAMA Cardiology</i> , 2017, 2, 1277. | 3.0 | 46 |
| 159 | Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. <i>Heart Failure Reviews</i> , 2022, 27, 337-344. | 1.7 | 46 |
| 160 | Comparing the Benefit of Novel Therapies Across Clinical Trials. <i>Circulation</i> , 2020, 142, 717-719. | 1.6 | 46 |
| 161 | Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437. | 0.7 | 46 |
| 162 | Extent and distribution of coronary artery disease: A comparative study of invasive versus noninvasive angiography with computed angiography. <i>American Heart Journal</i> , 2007, 153, 378-384. | 1.2 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Echocardiography, Natriuretic Peptides, and Risk for Incident Heart Failure in Older Adults. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 131-140. | 2.3 | 45 |
| 164 | Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1072-1081. | 2.9 | 44 |
| 165 | Risk Profiles in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007132. | 1.6 | 44 |
| 166 | Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. <i>American Heart Journal</i> , 2017, 189, 177-183. | 1.2 | 43 |
| 167 | Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. <i>Advances in Therapy</i> , 2020, 37, 4015-4032. | 1.3 | 43 |
| 168 | Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. <i>JACC: Heart Failure</i> , 2021, 9, 28-38. | 1.9 | 43 |
| 169 | Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2343-2354. | 2.3 | 42 |
| 170 | Atrial Fibrillation and Declining Physical Performance in Older Adults. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003525. | 2.1 | 41 |
| 171 | Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart OMics in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , 2017, 6, . | 1.6 | 41 |
| 172 | Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , 2020, 7, 76-84. | 1.4 | 41 |
| 173 | Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 137-150. | 0.4 | 41 |
| 174 | Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168. | 2.9 | 41 |
| 175 | Strategies and Opportunities for Drug Development in Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1593. | 3.8 | 40 |
| 176 | Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2016, 5, . | 1.6 | 40 |
| 177 | Therapeutic Manipulation of Myocardial Metabolism. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2022-2039. | 1.2 | 40 |
| 178 | The Cardio-Renal Interrelationship. <i>Progress in Cardiovascular Diseases</i> , 2017, 59, 636-648. | 1.6 | 39 |
| 179 | Relation of Living in a Food Desert to Recurrent Hospitalizations in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 123, 291-296. | 0.7 | 39 |
| 180 | Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 313-320. | 0.8 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. <i>European Heart Journal</i> , 2022, 43, 3435-3446. | 1.0 | 39 |
| 182 | Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451. | 1.0 | 38 |
| 183 | Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e005875. | 1.6 | 38 |
| 184 | Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598. | 1.2 | 38 |
| 185 | Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451. | 1.0 | 38 |
| 186 | Need for Increased Awareness and Evidence-Based Therapies for Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2035. | 3.8 | 37 |
| 187 | Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. <i>Circulation: Heart Failure</i> , 2018, 11, e004312. | 1.6 | 37 |
| 188 | “Time is prognosis”™ in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453. | 1.4 | 37 |
| 189 | Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400. | 1.6 | 36 |
| 190 | Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002797. | 3.9 | 36 |
| 191 | Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1129-1137. | 1.2 | 36 |
| 192 | Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1354-1362. | 0.8 | 35 |
| 193 | Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. <i>Clinical Research in Cardiology</i> , 2016, 105, 489-507. | 1.5 | 35 |
| 194 | Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928. | 4.3 | 35 |
| 195 | Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312. | 2.9 | 35 |
| 196 | Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408. | 1.6 | 34 |
| 197 | Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. <i>American Heart Journal</i> , 2014, 168, 142-149. | 1.2 | 34 |
| 198 | Contemporary Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 826-831. | 1.6 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002115. | 1.6 | 34 |
| 200 | Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1861-1871. | 1.2 | 34 |
| 201 | Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2018, 50, 1757-1766. | 0.2 | 34 |
| 202 | Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. <i>Internal and Emergency Medicine</i> , 2015, 10, 965-972. | 1.0 | 33 |
| 203 | Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291. | 2.9 | 33 |
| 204 | Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998. | 1.6 | 33 |
| 205 | Use of sodium-glucose cotransporter 2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 604-617. | 2.9 | 33 |
| 206 | Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022. | 2.9 | 33 |
| 207 | Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4455-4464. | 1.0 | 33 |
| 208 | Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265. | 0.7 | 32 |
| 209 | Cardiomyopathy and Heart Failure in Patients With HIV Infection. <i>Canadian Journal of Cardiology</i> , 2019, 35, 299-309. | 0.8 | 32 |
| 210 | Patiomer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238. | 2.9 | 32 |
| 211 | Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715. | 2.9 | 32 |
| 212 | Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation. <i>Annals of Internal Medicine</i> , 2022, 175, 1073-1082. | 2.0 | 32 |
| 213 | Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 428-438. | 0.7 | 31 |
| 214 | Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 933-941. | 1.9 | 31 |
| 215 | Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020, 22, 1065-1075. | 2.9 | 31 |
| 216 | Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735. | 1.9 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Representativeness of a Heart Failure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992. | 1.9 | 30 |
| 218 | Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. Circulation: Heart Failure, 2021, 14, e008100. | 1.6 | 30 |
| 219 | Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538. | 2.9 | 30 |
| 220 | Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43, 2984-2993. | 1.0 | 30 |
| 221 | Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. Circulation: Heart Failure, 2016, 9, e002444. | 1.6 | 29 |
| 222 | β_1 -Adrenoreceptor Autoantibodies in Heart Failure. Circulation: Heart Failure, 2020, 13, e006155. | 1.6 | 29 |
| 223 | Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. European Journal of Heart Failure, 2021, 23, 1468-1476. | 2.9 | 29 |
| 224 | Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology, 2022, 10, 35-45. | 5.5 | 29 |
| 225 | Nitrate Therapy for Heart Failure. JACC: Heart Failure, 2013, 1, 183-191. | 1.9 | 28 |
| 226 | Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. ESC Heart Failure, 2018, 5, 549-551. | 1.4 | 28 |
| 227 | Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e006946. | 1.6 | 28 |
| 228 | Endpoints in Heart Failure Drug Development. JACC: Heart Failure, 2020, 8, 429-440. | 1.9 | 28 |
| 229 | Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182. | 1.6 | 28 |
| 230 | Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. American Journal of Cardiology, 2015, 116, 474-480. | 0.7 | 27 |
| 231 | High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 748-755. | 2.9 | 27 |
| 232 | Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610. | 2.9 | 27 |
| 233 | Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure, 2019, 21, 1426-1433. | 2.9 | 27 |
| 234 | Salt, No Salt, or Less Salt for Patients With Heart Failure?. American Journal of Medicine, 2020, 133, 32-38. | 0.6 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031. | 2.9 | 27 |
| 236 | Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410. | 1.6 | 27 |
| 237 | Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , 2015, 170, 263-272.e2. | 1.2 | 26 |
| 238 | Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016, 21, 455-462. | 1.7 | 26 |
| 239 | Prognostic significance of ¹²³ I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 384-390. | 0.5 | 26 |
| 240 | Echocardiography in Acute Heart Failure: Current Perspectives. <i>Journal of Cardiac Failure</i> , 2016, 22, 82-94. | 0.7 | 26 |
| 241 | A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. <i>American Journal of Cardiology</i> , 2017, 120, 1440-1449. | 0.7 | 26 |
| 242 | Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2018, 137, 1060-1073. | 1.6 | 26 |
| 243 | Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, . | 1.6 | 26 |
| 244 | Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12. | 1.9 | 26 |
| 245 | In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. <i>European Journal of Heart Failure</i> , 2022, 24, 227-229. | 2.9 | 26 |
| 246 | Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248. | 2.9 | 26 |
| 247 | Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. <i>Journal of Cardiac Failure</i> , 2015, 21, 555-560. | 0.7 | 25 |
| 248 | The Vulnerable Phase of Heart Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e456-e464. | 0.5 | 25 |
| 249 | Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380. | 0.7 | 25 |
| 250 | Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833. | 1.6 | 25 |
| 251 | The Right Ventricular Function After Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 429-437. | 0.5 | 24 |
| 252 | Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , 2018, 11, e005629. | 1.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , 2018, 138, 1039-1053. | 1.6 | 24 |
| 254 | Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1675-1683. | 2.9 | 24 |
| 255 | Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871. | 1.6 | 24 |
| 256 | Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. <i>Advances in Therapy</i> , 2015, 32, 971-982. | 1.3 | 23 |
| 257 | Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 350-352. | 2.9 | 23 |
| 258 | Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150. | 0.7 | 23 |
| 259 | Influence of atrial fibrillation on postdischarge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562. | 2.9 | 23 |
| 260 | Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , 2018, 269, 265-271. | 0.8 | 23 |
| 261 | A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , 2020, 130, 159-161. | 0.7 | 23 |
| 262 | Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345. | 1.9 | 23 |
| 263 | Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252. | 1.8 | 23 |
| 264 | Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598. | 1.2 | 23 |
| 265 | Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180. | 2.9 | 23 |
| 266 | DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101. | 1.2 | 23 |
| 267 | Relation of the Metabolic Syndrome to Quantity of Coronary Atherosclerotic Plaque. <i>American Journal of Cardiology</i> , 2008, 101, 1127-1130. | 0.7 | 22 |
| 268 | Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179. | 0.7 | 22 |
| 269 | Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118. | 1.6 | 22 |
| 270 | Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 78-86. | 0.7 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50. | 1.2 | 22 |
| 272 | Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267. | 3.0 | 22 |
| 273 | Contextualizing Risk Among Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2261. | 3.8 | 22 |
| 274 | The need for increased pragmatism in cardiovascular clinical trials. <i>Nature Reviews Cardiology</i> , 2022, 19, 737-750. | 6.1 | 22 |
| 275 | The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 399-407. | 0.9 | 21 |
| 276 | Comparing Sodium Intake Strategies in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 636-645. | 1.6 | 21 |
| 277 | Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , 2018, 5, 139-148. | 1.4 | 21 |
| 278 | Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , 2018, 6, 813-822. | 1.9 | 21 |
| 279 | Timely Management of New-Onset Heart Failure. <i>Circulation</i> , 2019, 140, 621-623. | 1.6 | 21 |
| 280 | Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499. | 1.6 | 21 |
| 281 | Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <sc>EMPERORâ€Preserved</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799. | 2.9 | 21 |
| 282 | Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. <i>Journal of the American College of Cardiology</i> , 2022, 79, 432-444. | 1.2 | 21 |
| 283 | Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510. | 1.2 | 21 |
| 284 | Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. <i>JACC: Heart Failure</i> , 2022, 10, 350-362. | 1.9 | 21 |
| 285 | Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPERORâ€Preserved</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1869-1878. | 2.9 | 21 |
| 286 | Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18. | 1.2 | 21 |
| 287 | Improving cardiovascular clinical trials conduct in the United States: Recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , 2015, 169, 305-314. | 1.2 | 20 |
| 288 | Antecedents of self-care in adults with congenital heart defects. <i>International Journal of Cardiology</i> , 2015, 201, 610-615. | 0.8 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 289 | New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , 2016, 216, 46-51. | 0.8 | 20 |
| 290 | SPECT and PET in ischemic heart failure. <i>Heart Failure Reviews</i> , 2017, 22, 243-261. | 1.7 | 20 |
| 291 | Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 20 |
| 292 | Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2305-2318. | 2.3 | 20 |
| 293 | Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 58) | 0.7 | 20 |
| 294 | Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. <i>European Heart Journal</i> , 2020, 41, 3398-3401. | 1.0 | 20 |
| 295 | Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1141-1150. | 2.2 | 20 |
| 296 | Advanced cancer is also a heart failure syndrome: a hypothesis. <i>European Journal of Heart Failure</i> , 2021, 23, 140-144. | 2.9 | 20 |
| 297 | Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 42-51. | 1.9 | 20 |
| 298 | Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 266-275. | 1.9 | 20 |
| 299 | An Economic Evaluation of a Self-Care Intervention in Persons With Heart Failure and Diabetes. <i>Journal of Cardiac Failure</i> , 2015, 21, 730-737. | 0.7 | 19 |
| 300 | Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 340-346. | 0.7 | 19 |
| 301 | Comparison of Hydralazine/Nitrate and Angiotensin Receptor Nephilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , 2019, 124, 1900-1906. | 0.7 | 19 |
| 302 | Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105. | 0.8 | 19 |
| 303 | Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. <i>International Journal of Cardiology</i> , 2020, 300, 245-251. | 0.8 | 19 |
| 304 | Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014990. | 1.6 | 19 |
| 305 | Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 2393-2398. | 2.9 | 19 |
| 306 | Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2021, 10, e017320. | 1.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Systemic inflammation and functional capacity in elderly heart failure patients. <i>Clinical Research in Cardiology</i> , 2018, 107, 362-367. | 1.5 | 18 |
| 308 | Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 152-154. | 1.6 | 18 |
| 309 | Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>JAMA Cardiology</i> , 2021, 6, 200. | 3.0 | 18 |
| 310 | Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. <i>European Journal of Heart Failure</i> , 2021, 23, 145-153. | 2.9 | 18 |
| 311 | Thromboembolism in Heart Failure Patients in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2021, 9, 243-253. | 1.9 | 18 |
| 312 | Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 17 |
| 313 | Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , 2018, 20, 1068-1071. | 2.9 | 17 |
| 314 | Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947. | 1.6 | 17 |
| 315 | Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e475-e486. | 0.5 | 17 |
| 316 | Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1247-1251. | 2.9 | 17 |
| 317 | Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020, 180, 141. | 2.6 | 17 |
| 318 | Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2432-2447. | 1.2 | 17 |
| 319 | Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , 2021, 23, 1250-1255. | 2.9 | 17 |
| 320 | Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial. <i>European Journal of Heart Failure</i> , 2022, , . | 2.9 | 17 |
| 321 | Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , 2015, 17, 760-763. | 2.9 | 16 |
| 322 | The Potential Role of Natriuretic Peptide-Guided Management for Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 233-239. | 0.7 | 16 |
| 323 | Platelet-Derived Growth Factor in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 355-369. | 0.9 | 16 |
| 324 | Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective. <i>ESC Heart Failure</i> , 2020, 7, 3261-3267. | 1.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. <i>Heart Lung and Circulation</i> , 2021, 30, 786-794. | 0.2 | 16 |
| 326 | Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2021, 27, 2-19. | 0.7 | 16 |
| 327 | Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676. | 0.7 | 16 |
| 328 | Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. <i>European Journal of Heart Failure</i> , 2022, 24, 455-462. | 2.9 | 16 |
| 329 | Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384. | 0.7 | 16 |
| 330 | Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790. | 2.9 | 16 |
| 331 | Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210. | 1.9 | 16 |
| 332 | Inotrope Use and Outcomes Among Patients Hospitalized for Heart Failure: Impact of Systolic Blood Pressure, Cardiac Index, and Etiology. <i>Journal of Cardiac Failure</i> , 2014, 20, 593-601. | 0.7 | 15 |
| 333 | Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, . | 1.6 | 15 |
| 334 | Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 0.7 | 15 |
| 335 | Exercise Capacity, Heart Failure Risk, and Mortality in Older Adults: The Health ABC Study. <i>American Journal of Preventive Medicine</i> , 2017, 52, 144-153. | 1.6 | 15 |
| 336 | Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668. | 0.9 | 15 |
| 337 | Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225. | 0.6 | 15 |
| 338 | Predictors of heart failure development in type 2 diabetes. <i>Current Opinion in Cardiology</i> , 2019, 34, 578-583. | 0.8 | 15 |
| 339 | Therapeutic Advances in the Management of Cardiogenic Shock. <i>American Journal of Therapeutics</i> , 2019, 26, e234-e247. | 0.5 | 15 |
| 340 | Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 1600-1610. | 2.9 | 15 |
| 341 | Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006827. | 1.6 | 15 |
| 342 | Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 354. | 3.0 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 146, 36-47. | 0.7 | 15 |
| 344 | Treatment patterns and clinical outcomes among patients <65&€%years with a worsening heart failure event. <i>European Journal of Heart Failure</i> , 2021, 23, 1334-1342. | 2.9 | 15 |
| 345 | Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832. | 2.9 | 15 |
| 346 | Association of electrocardiogram abnormalities and incident heart failure events. <i>American Heart Journal</i> , 2014, 167, 869-875.e3. | 1.2 | 14 |
| 347 | Reassessing Phase II Heart Failure Clinical Trials. <i>Circulation: Heart Failure</i> , 2017, 10, . | 1.6 | 14 |
| 348 | Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1207-1213. | 0.7 | 14 |
| 349 | Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. <i>Current Heart Failure Reports</i> , 2018, 15, 191-197. | 1.3 | 14 |
| 350 | Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , 2018, 36, 1463-1473. | 1.7 | 14 |
| 351 | Clinical aspects of heart failure in individuals with diabetes. <i>Diabetologia</i> , 2019, 62, 1529-1538. | 2.9 | 14 |
| 352 | Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. <i>European Journal of Heart Failure</i> , 2019, 21, 121-124. | 2.9 | 14 |
| 353 | Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2486-2497. | 1.3 | 14 |
| 354 | Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895. | 0.7 | 14 |
| 355 | Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. <i>American Journal of Medicine</i> , 2021, 134, 1068-1070. | 0.6 | 14 |
| 356 | Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. <i>JAMA Cardiology</i> , 2022, 7, 549. | 3.0 | 14 |
| 357 | Outcomes with empagliflozin in heart failure with preserved ejection fraction using <sc>DELIVER</sc> &€like endpoint definitions. <i>European Journal of Heart Failure</i> , 2022, 24, 1400-1405. | 2.9 | 14 |
| 358 | Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> , 2022, 43, 2931-2945. | 1.0 | 14 |
| 359 | Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2016, 18, 185-191. | 2.9 | 13 |
| 360 | Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , 2017, 14, 217-222. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783. | 0.9 | 13 |
| 362 | Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. <i>European Heart Journal Supplements</i> , 2019, 21, A20-A27. | 0.0 | 13 |
| 363 | Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. <i>JACC: Heart Failure</i> , 2019, 7, 267-271. | 1.9 | 13 |
| 364 | Acutely decompensated versus acute heart failure: two different entities. <i>Heart Failure Reviews</i> , 2020, 25, 907-916. | 1.7 | 13 |
| 365 | Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451. | 1.4 | 13 |
| 366 | Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020, 43, 2684-2690. | 4.3 | 13 |
| 367 | Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1243-1262. | 2.2 | 13 |
| 368 | Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 741-753. | 1.7 | 13 |
| 369 | Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 1583-1594. | 2.9 | 13 |
| 370 | Advanced cancer is also a heart failure syndrome: a hypothesis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 533-537. | 2.9 | 13 |
| 371 | Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1374-1381. | 0.7 | 13 |
| 372 | Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , 2021, 6, 2752-2762. | 0.4 | 13 |
| 373 | Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 485-493. | 1.9 | 13 |
| 374 | Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671. | 2.9 | 12 |
| 375 | The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 1-14. | 0.9 | 12 |
| 376 | Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346. | 0.7 | 12 |
| 377 | Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 210-216. | 1.3 | 12 |
| 378 | Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2018, 15, 44-52. | 1.3 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 379 | Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , 2018, 36, 63-72. | 0.9 | 12 |
| 380 | Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008. | 1.9 | 12 |
| 381 | Victims of Success in Failure. <i>Circulation</i> , 2020, 142, 1129-1131. | 1.6 | 12 |
| 382 | Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006389. | 1.6 | 12 |
| 383 | Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461. | 2.9 | 12 |
| 384 | Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. <i>ESC Heart Failure</i> , 2021, 8, 1915-1923. | 1.4 | 12 |
| 385 | Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. <i>Circulation</i> , 2021, 143, 2329-2331. | 1.6 | 12 |
| 386 | Maternal Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e021019. | 1.6 | 12 |
| 387 | Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784. | 2.2 | 12 |
| 388 | How well do we represent ourselves: an analysis of cardiology fellowships website content. <i>Future Cardiology</i> , 2020, 16, 281-287. | 0.5 | 12 |
| 389 | Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850. | 0.7 | 11 |
| 390 | Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 768-776. | 0.8 | 11 |
| 391 | Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. <i>JAMA Cardiology</i> , 2017, 2, 1263. | 3.0 | 11 |
| 392 | A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 783-792. | 0.7 | 11 |
| 393 | Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711. | 0.7 | 11 |
| 394 | Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , 2021, 8, 16-25. | 1.4 | 11 |
| 395 | Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300. | 0.8 | 11 |
| 396 | Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890. | 1.0 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Impact of polyvascular disease with and without coexisting kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. Diabetes, Obesity and Metabolism, 2021, 23, 1173-1181. | 2.2 | 11 |
| 398 | Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. Journal of the American Heart Association, 2020, 9, e015752. | 1.6 | 11 |
| 399 | Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC: Heart Failure, 2022, 10, 1-11. | 1.9 | 11 |
| 400 | Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153. | 2.9 | 11 |
| 401 | Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931. | 0.8 | 10 |
| 402 | Therapeutic Advances in the Management of Acute Decompensated Heart Failure. American Journal of Therapeutics, 2019, 26, e222-e233. | 0.5 | 10 |
| 403 | Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. European Journal of Heart Failure, 2019, 21, 235-237. | 2.9 | 10 |
| 404 | History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. JACC: Heart Failure, 2019, 7, 47-55. | 1.9 | 10 |
| 405 | Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal of Cardiac Failure, 2020, 26, 270-275. | 0.7 | 10 |
| 406 | Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. ESC Heart Failure, 2020, 7, 3531-3535. | 1.4 | 10 |
| 407 | Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. Journal of the American College of Cardiology, 2020, 76, 2517-2521. | 1.2 | 10 |
| 408 | The Limitations of Symptom-based Heart Failure Management. Cardiac Failure Review, 2019, 5, 74-77. | 1.2 | 10 |
| 409 | Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. Circulation: Heart Failure, 2021, 14, e008351. | 1.6 | 10 |
| 410 | Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Failure, 2022, 9, 685-694. | 1.4 | 10 |
| 411 | Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts. Circulation, 2022, 145, 268-278. | 1.6 | 10 |
| 412 | Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation: Heart Failure, 2022, 15, . | 1.6 | 10 |
| 413 | Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2022, 24, 1625-1632. | 2.9 | 10 |
| 414 | Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. Expert Review of Cardiovascular Therapy, 2015, 13, 1075-1078. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 415 | Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events. <i>Acute Cardiac Care</i> , 2016, 18, 56-64. | 0.2 | 9 |
| 416 | Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , 2016, 175, 142-152. | 1.2 | 9 |
| 417 | Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303. | 0.8 | 9 |
| 418 | Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 314-315. | 5.5 | 9 |
| 419 | The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure. <i>Circulation</i> , 2017, 136, 1459-1461. | 1.6 | 9 |
| 420 | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519. | 0.7 | 9 |
| 421 | Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , 2018, 20, 1379-1381. | 2.9 | 9 |
| 422 | Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 705-713. | 0.5 | 9 |
| 423 | Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. <i>Children</i> , 2021, 8, 322. | 0.6 | 9 |
| 424 | What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021, 42, 2373-2383. | 1.0 | 9 |
| 425 | Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1477-1484. | 2.9 | 9 |
| 426 | Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of "too little, too late". <i>European Journal of Heart Failure</i> , 2021, 23, 1514-1517. | 2.9 | 9 |
| 427 | Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 857538. | 1.3 | 9 |
| 428 | Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. <i>International Journal of Cardiology</i> , 2016, 218, 136-143. | 0.8 | 8 |
| 429 | Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, . | 1.6 | 8 |
| 430 | Heart failure guidelines: What's new?. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 316-323. | 2.3 | 8 |
| 431 | Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 537-560. | 0.9 | 8 |
| 432 | Integrating electronic health records into the study of heart failure: promises and pitfalls. <i>European Journal of Heart Failure</i> , 2017, 19, 1128-1130. | 2.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 433 | A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421. | 0.6 | 8 |
| 434 | Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 714-717. | 1.9 | 8 |
| 435 | Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. <i>Digital Biomarkers</i> , 2020, 4, 45-59. | 2.2 | 8 |
| 436 | The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008030. | 1.6 | 8 |
| 437 | Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017018. | 1.6 | 8 |
| 438 | Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163. | 1.2 | 8 |
| 439 | Functional outcomes with Carillon device over 1Âyear in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCEâ€FMR trial. <i>ESC Heart Failure</i> , 2021, 8, 872-878. | 1.4 | 8 |
| 440 | Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, 145, 165-168. | 0.7 | 8 |
| 441 | Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. <i>Mayo Clinic Proceedings</i> , 2021, 96, 901-911. | 1.4 | 8 |
| 442 | Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2022, 27, 1147-1163. | 1.7 | 8 |
| 443 | The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from <sc>CHAMPâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 762-770. | 2.9 | 8 |
| 444 | Responder analysis for improvement in sixâ€minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, , . | 2.9 | 8 |
| 445 | Defining changes in physical limitation from the patient perspective: insights from the <sc>VITALITYâ€HFpEF</sc> randomized trial. <i>European Journal of Heart Failure</i> , 2022, , . | 2.9 | 8 |
| 446 | Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400. | 1.0 | 8 |
| 447 | Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, . | 0.7 | 8 |
| 448 | Heart Failure: A Global Pandemic and Not Just a Disease of the West. <i>Heart Failure Clinics</i> , 2015, 11, xiii-xiv. | 1.0 | 7 |
| 449 | Diagnosis and Prevention of Hypertensive Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 435-445. | 1.0 | 7 |
| 450 | Novel potassium binders as enabling therapy in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 550-552. | 2.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 451 | Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. <i>International Journal of Cardiology</i> , 2020, 304, 116-121. | 0.8 | 7 |
| 452 | Recognizing the Significance of Outpatient Worsening Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017485. | 1.6 | 7 |
| 453 | Benefitâ€“Risk Tradeoffs in Assessment of New Drugs and Devices. <i>Circulation</i> , 2020, 142, 1974-1988. | 1.6 | 7 |
| 454 | Challenges and Potential Improvements to Patient Access to Pharmaceuticals. <i>Circulation</i> , 2020, 142, 790-798. | 1.6 | 7 |
| 455 | The real world of <i>de novo</i> heart failure: the next frontier for heart failure clinical trials?. <i>European Journal of Heart Failure</i> , 2020, 22, 1786-1789. | 2.9 | 7 |
| 456 | SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. <i>Current Cardiology Reports</i> , 2021, 23, 59. | 1.3 | 7 |
| 457 | Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , 2021, 235, 82-96. | 1.2 | 7 |
| 458 | Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left VentricularÂEnlargement. <i>JACC: Heart Failure</i> , 2021, 9, 453-462. | 1.9 | 7 |
| 459 | Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. <i>European Journal of Heart Failure</i> , 2021, 23, 1525-1528. | 2.9 | 7 |
| 460 | Health Systemâ€“Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , . | 0.7 | 7 |
| 461 | Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018, 15, 10-16. | 1.3 | 6 |
| 462 | Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 597-607. | 1.7 | 6 |
| 463 | Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314,rgBT /Overlock | 0.7 | 6 |
| 464 | Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2018, 272, 250-254. | 0.8 | 6 |
| 465 | Design of a â€œLeanâ€“Case Report Form for HeartÂFailure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921. | 1.9 | 6 |
| 466 | New treatments for hyperkalaemia: clinical use in cardiology. <i>European Heart Journal Supplements</i> , 2019, 21, A41-A47. | 0.0 | 6 |
| 467 | SGLT-2 inhibitors in heart failure: a new therapeutic avenue. <i>Nature Medicine</i> , 2019, 25, 1653-1654. | 15.2 | 6 |
| 468 | Cardiac Imaging in Dialysis Patients. <i>Kidney Medicine</i> , 2020, 2, 629-638. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | Ten lessons from the <sc>EMPEROR</sc> Reduced trial. European Journal of Heart Failure, 2020, 22, 1991-1993. | 2.9 | 6 |
| 470 | Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. Circulation: Heart Failure, 2020, 13, e007070. | 1.6 | 6 |
| 471 | Istaroxime in acute heart failure: the holy grail is at HORIZON?. European Journal of Heart Failure, 2020, 22, 1694-1697. | 2.9 | 6 |
| 472 | Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. American Journal of Medicine, 2020, 133, 525-527. | 0.6 | 6 |
| 473 | Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36. | 1.4 | 6 |
| 474 | Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. European Heart Journal, 2022, 43, 2968-2970. | 1.0 | 6 |
| 475 | Challenges and the innovations in the care of advanced heart failure patients during COVID-19. Heart Failure Reviews, 2022, 27, 235-238. | 1.7 | 6 |
| 476 | Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. ESC Heart Failure, 2021, 8, 1885-1891. | 1.4 | 6 |
| 477 | Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, 191-201. | 0.7 | 6 |
| 478 | Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. American Heart Journal, 2020, 230, 71-81. | 1.2 | 6 |
| 479 | Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. Circulation: Heart Failure, 2022, 15, . | 1.6 | 6 |
| 480 | Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure. Heart Failure Clinics, 2014, 10, 565-576. | 1.0 | 5 |
| 481 | Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. American Journal of Cardiology, 2015, 116, 1304-1310. | 0.7 | 5 |
| 482 | Updates on Device-Based Therapies for Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 53-60. | 1.3 | 5 |
| 483 | The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. JACC: Clinical Electrophysiology, 2018, 4, 944-954. | 1.3 | 5 |
| 484 | Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. PLoS ONE, 2019, 14, e0222868. | 1.1 | 5 |
| 485 | Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). American Journal of Cardiology, 2019, 123, 1660-1666. | 0.7 | 5 |
| 486 | From <sc>PARADIGM</sc> to <sc>PARAGON</sc> further evidence supporting continuous heart failure spectrum. European Journal of Heart Failure, 2020, 22, 1536-1539. | 2.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 487 | Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. ESC Heart Failure, 2021, 8, 662-669. | 1.4 | 5 |
| 488 | Can we trust a smartwatch <scp>ECG</scp>? Potential and limitations. European Journal of Heart Failure, 2021, 23, 850-853. | 2.9 | 5 |
| 489 | Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007956. | 0.9 | 5 |
| 490 | Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 916-923. | 0.7 | 5 |
| 491 | Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984. | 2.9 | 5 |
| 492 | Response to Sexton: Inhibiting the Renin-“Angiotensin”-Aldosterone System in Patients With Heart Failure and Renal Dysfunction. Circulation: Heart Failure, 2014, 7, 537-540. | 1.6 | 4 |
| 493 | Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627. | 0.7 | 4 |
| 494 | Is Time of the Essence? The Impact of “Time of Hospital Presentation in Acute” Heart Failure. JACC: Heart Failure, 2018, 6, 298-307. | 1.9 | 4 |
| 495 | Past, present, and future of acute heart failure clinical trials “a high-risk population in search of a strategy. European Journal of Heart Failure, 2018, 20, 839-841. | 2.9 | 4 |
| 496 | Optimal Endpoints of Acute Heart Failure Therapy. American Journal of Therapeutics, 2018, 25, e465-e474. | 0.5 | 4 |
| 497 | Epirubicin and long-term heart failure risk in breast cancer survivors. European Journal of Heart Failure, 2018, 20, 1454-1456. | 2.9 | 4 |
| 498 | Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Pregnancy Hypertension, 2020, 21, 184-190. | 0.6 | 4 |
| 499 | Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. European Journal of Heart Failure, 2020, 22, 1019-1021. | 2.9 | 4 |
| 500 | Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. Heart Failure Reviews, 2021, 26, 381-389. | 1.7 | 4 |
| 501 | Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563. | 0.7 | 4 |
| 502 | Robustness of outcomes in trials evaluating sodium “glucose co-transporter 2 inhibitors for heart failure. ESC Heart Failure, 2022, , . | 1.4 | 4 |
| 503 | Updated Heart Failure Guidelines: Time for a Refresh. Circulation, 2022, 145, 1371-1373. | 1.6 | 4 |
| 504 | Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. Current Heart Failure Reports, 2017, 14, 203-209. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 505 | FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i72-i72. | 0.4 | 3 |
| 506 | Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1267-1269. | 2.9 | 3 |
| 507 | Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. <i>Current Diabetes Reports</i> , 2019, 19, 39. | 1.7 | 3 |
| 508 | Prescription drug spending and hospital use among Medicare beneficiaries with heart failure. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1452-1458. | 1.5 | 3 |
| 509 | Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2020, 22, 164-167. | 2.9 | 3 |
| 510 | Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , 2020, 136, 100-106. | 0.7 | 3 |
| 511 | The role of sodium glucose co-transporter inhibitors in heart failure prevention. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107811. | 1.2 | 3 |
| 512 | INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 849-860. | 1.4 | 3 |
| 513 | Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017932. | 1.6 | 3 |
| 514 | Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53. | 1.2 | 3 |
| 515 | Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185. | 1.4 | 3 |
| 516 | Ejection fraction in heart failure: just become Emperor's new clothes?. <i>European Journal of Heart Failure</i> , 2022, 24, 351-352. | 2.9 | 3 |
| 517 | Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. <i>Journal of Family Practice</i> , 2017, 66, S16-S21. | 0.2 | 3 |
| 518 | Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. <i>Journal of the American Heart Association</i> , 2022, 11, . | 1.6 | 3 |
| 519 | Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. <i>American Journal of Medicine</i> , 2014, 127, 574-578. | 0.6 | 2 |
| 520 | Disrupting Virchow's triad: can factor X inhibition reduce risk of adverse outcomes in patients with ischaemic cardiomyopathy?. <i>European Journal of Heart Failure</i> , 2015, 17, 647-651. | 2.9 | 2 |
| 521 | Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015, 116, 307-312. | 0.7 | 2 |
| 522 | Cardiac Contractility Modulation: The Next Cardiac Resynchronization Therapy or Another Renal Sympathetic Denervation?. <i>Journal of Cardiac Failure</i> , 2015, 21, 24-26. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 523 | Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016, 214, 16-18. | 0.8 | 2 |
| 524 | Diabetes Mellitus in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 25-27. | 1.9 | 2 |
| 525 | Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1760-1763. | 2.9 | 2 |
| 526 | Revisiting hyperkalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , 2018, 20, 1255-1255. | 2.9 | 2 |
| 527 | <i>De novo</i> heart failure: where the journey begins. <i>European Journal of Heart Failure</i> , 2019, 21, 1245-1247. | 2.9 | 2 |
| 528 | Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1426-1427. | 1.2 | 2 |
| 529 | Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476. | 2.9 | 2 |
| 530 | Targeting Mitochondrial Function in Heart Failure. <i>JACC Basic To Translational Science</i> , 2019, 4, 158-160. | 1.9 | 2 |
| 531 | Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). <i>American Journal of Cardiology</i> , 2020, 125, 82-86. | 0.7 | 2 |
| 532 | Angiotensin-neprilysin inhibition in <i>de novo</i> heart failure “starting off strong”. <i>European Journal of Heart Failure</i> , 2020, 22, 313-314. | 2.9 | 2 |
| 533 | Heart Failure Prevention for All. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1466-1467. | 1.2 | 2 |
| 534 | Sodium-glucose cotransporter 2 inhibitors: “a tale of two sisters”, diabetes and heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1259-1262. | 2.9 | 2 |
| 535 | Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006509. | 0.9 | 2 |
| 536 | Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1577-1581. | 0.7 | 2 |
| 537 | Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , 2021, 142, 153-155. | 0.7 | 2 |
| 538 | Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1. | 0.7 | 2 |
| 539 | Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction “time to think outside the heart”. <i>European Journal of Heart Failure</i> , 2021, 23, 1552-1554. | 2.9 | 2 |
| 540 | Hypertensive Diseases in Pregnancy and Kidney Function Later in Life. <i>Mayo Clinic Proceedings</i> , 2022, 97, 78-87. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 541 | Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008072. | 0.9 | 2 |
| 542 | The Syndrome of Heart Failure With Preserved Systolic Function. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 232-233. | 0.4 | 1 |
| 543 | Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , 2018, 20, 97. | 1.3 | 1 |
| 544 | Questioning the Associations of ω -3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 781. | 3.0 | 1 |
| 545 | Mid-regional proatrial natriuretic peptide for diagnosis of heart failure in nonacute settings: biomarkers plus clinical sense make good sense. <i>European Journal of Heart Failure</i> , 2019, 21, 1228-1230. | 2.9 | 1 |
| 546 | The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial. <i>European Journal of Heart Failure</i> , 2019, 21, 334-336. | 2.9 | 1 |
| 547 | Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. <i>Journal of Diabetes</i> , 2019, 11, 601-604. | 0.8 | 1 |
| 548 | Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?. <i>Current Heart Failure Reports</i> , 2019, 16, 12-20. | 1.3 | 1 |
| 549 | Commentary: Failure predicting failure: The right ventricle after left ventricular assist device implantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1861-1862. | 0.4 | 1 |
| 550 | Disparities in Discharge Disposition After Hospitalizations for Decompensated Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 95-97. | 0.3 | 1 |
| 551 | Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529. | 1.7 | 1 |
| 552 | FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, . | 0.4 | 1 |
| 553 | Hostile Work Environment. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2410-2412. | 1.2 | 1 |
| 554 | Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , 2021, 14, e008147. | 1.6 | 1 |
| 555 | Target trial emulations: bridging the gap between clinical trial and real-world data. <i>European Journal of Heart Failure</i> , 2021, 23, 1708-1711. | 2.9 | 1 |
| 556 | Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126. | 0.7 | 1 |
| 557 | Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032. | | 1 |
| 558 | Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. <i>Cardiac Failure Review</i> , 2019, 5, 169-172. | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 559 | Investigator-Reported Versus Adjudicated Clinical Events. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1538-1540. | 1.2 | 1 |
| 560 | Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 271-281. | 0.1 | 1 |
| 561 | Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. <i>European Journal of Heart Failure</i> , 2022, 24, 678-680. | 2.9 | 1 |
| 562 | Assessing health status after discharge for decompensated heart failure: a patient-centred priority. <i>European Journal of Heart Failure</i> , 2022, 24, 1030-1032. | 2.9 | 1 |
| 563 | Response to Letter Regarding Article, "Effect of Short Call Admissions on Length of Stay and Quality of Care for Acute Decompensated Heart Failure": <i>Circulation</i> , 2009, 119, . | 1.6 | 0 |
| 564 | The Hi-Tech Age of Heart Failure Management. <i>Heart Failure Clinics</i> , 2015, 11, xi-xii. | 1.0 | 0 |
| 565 | The Winning Team in Heart Failure: Dimensionality of Care Redesign. <i>Heart Failure Clinics</i> , 2015, 11, ix-x. | 1.0 | 0 |
| 566 | Biomarkers and Cancer Therapy-Related Cardiac Dysfunction. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1. | 0.8 | 0 |
| 567 | How to Best Identify Elderly Individuals Who May Develop Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1. | 0.8 | 0 |
| 568 | Dilemmas With Race and Heart Failure Treatment. <i>Circulation: Heart Failure</i> , 2016, 9, . | 1.6 | 0 |
| 569 | Left Ventricular Ejection Fraction in Patients With Acute Heart Failure: A Limited Tool?. <i>Revista Espanola De Cardiología (English Ed)</i> , 2017, 70, 318-319. | 0.4 | 0 |
| 570 | Leadership in cardiology. <i>European Heart Journal</i> , 2017, 38, 2323-2323. | 1.0 | 0 |
| 571 | Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 123-131. | 0.6 | 0 |
| 572 | Mihai Gheorghide, MD "Life and Concepts. <i>American Journal of Therapeutics</i> , 2018, 25, e453-e455. | 0.5 | 0 |
| 573 | With great power comes great reliability. <i>European Journal of Heart Failure</i> , 2020, 22, 1708-1710. | 2.9 | 0 |
| 574 | Standardizing the standard: reporting health status in clinical trials. <i>European Journal of Heart Failure</i> , 2021, 23, 203-204. | 2.9 | 0 |
| 575 | Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1. | 0.4 | 0 |
| 576 | Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials. <i>European Journal of Heart Failure</i> , 2021, 23, 590-592. | 2.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 577 | Aetiology of heart failure is in the eye of the beholder: does it even matter?. European Journal of Heart Failure, 2021, 23, 614-616. | 2.9 | 0 |
| 578 | The Reply. American Journal of Medicine, 2021, 134, e357. | 0.6 | 0 |
| 579 | Sex Disparity Among Canadian Cardiologists in Academic Medicine: Differences in Scholarly Productivity and Academic Rank. Cureus, 2021, 13, e18687. | 0.2 | 0 |
| 580 | Abstract 11614: ASC Methylation and Outcomes in Heart Failure. Circulation, 2015, 132, . | 1.6 | 0 |
| 581 | Abstract 10902: Association Between Funding Sources and the Scope and Outcomes of Cardiovascular Clinical Trials: A Systematic Review. Circulation, 2015, 132, . | 1.6 | 0 |
| 582 | Abstract 14841: Definitions of Stage D Heart Failure and Survival: Comparing INTERMACS Profiles, ESC Criteria, and Physician Assessment. Circulation, 2015, 132, . | 1.6 | 0 |
| 583 | Abstract 252: Regional Variations in Access to Care Among U.S. Veterans With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, . | 0.9 | 0 |
| 584 | The inadequacy of cardiovascular safety reporting in breast cancer clinical trials.. Journal of Clinical Oncology, 2020, 38, e24100-e24100. | 0.8 | 0 |
| 585 | Annals for Hospitalists Inpatient Notes - Clinical Pearls“Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, HO2-HO3. | 2.0 | 0 |
| 586 | The Enabling Potential of Device Therapy for Heart Failure. Journal of Cardiac Failure, 2022, , . | 0.7 | 0 |
| 587 | Uptitrating versus adding heart failure with reduced ejection fraction medications: bring more players to the game. European Journal of Heart Failure, 2022, 24, 885-886. | 2.9 | 0 |
| 588 | Abstract 19793: Relationship Between Self-care, Functional Health, and Health Resource Use in Adults With Congenital Heart Defects. Circulation, 2015, 132, . | 1.6 | 0 |
| 589 | Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial. Circulation, 2017, 136, . | 1.6 | 0 |
| 590 | Abstract 21161: Use of an Open Access Multi-Sponsor Data Sharing Platform in Cardiology. Circulation, 2017, 136, . | 1.6 | 0 |